Biolargo annual return on equity
2020
2021
2022
2023
2024
2025
Biolargo Return on Equity (ROE) Growth & History (BLGO)
Biolargo's return on equity was −235.62% for fiscal 2025.
View full Biolargo company overviewBiolargo annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −235.62% | −180.22 pp |
| 2024 | 2024-12-31 | −55.39% | +23.91 pp |
| 2023 | 2023-12-31 | −79.30% | +28.39 pp |
| 2022 | 2022-12-31 | −107.69% | +54.31 pp |
| 2021 | 2021-12-31 | −162.00% | +975.83 pp |
| 2020 | 2020-12-31 | −1,137.83% | — |
Biolargo quarterly return on equity
Q4.15
Q1.16
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | −116.85% | −93.51 pp |
| Q4 2025 | 2025-12-31 | −77.99% | −58.11 pp |
| Q3 2025 | 2025-09-30 | −94.48% | −79.94 pp |
| Q2 2025 | 2025-06-30 | −23.00% | −11.95 pp |
| Q1 2025 | 2025-03-31 | −23.34% | −12.98 pp |
| Q4 2024 | 2024-12-31 | −19.88% | −5.21 pp |
| Q3 2024 | 2024-09-30 | −14.54% | +6.35 pp |
| Q2 2024 | 2024-06-30 | −11.05% | +12.60 pp |
| Q1 2024 | 2024-03-31 | −10.36% | −1.59 pp |
| Q4 2023 | 2023-12-31 | −14.66% | +13.95 pp |
| Q3 2023 | 2023-09-30 | −20.89% | −2.94 pp |
| Q2 2023 | 2023-06-30 | −23.65% | +6.11 pp |
| Q1 2023 | 2023-03-31 | −8.77% | +25.02 pp |
| Q4 2022 | 2022-12-31 | −28.61% | +9.24 pp |
| Q3 2022 | 2022-09-30 | −17.95% | +11.12 pp |
| Q2 2022 | 2022-06-30 | −29.76% | +6.73 pp |
| Q1 2022 | 2022-03-31 | −33.79% | +9.85 pp |
| Q4 2021 | 2021-12-31 | −37.86% | +8.87 pp |
| Q3 2021 | 2021-09-30 | −29.07% | +36.30 pp |
| Q2 2021 | 2021-06-30 | −36.49% | — |
| Q1 2021 | 2021-03-31 | −43.64% | — |
| Q4 2020 | 2020-12-31 | −46.73% | — |
| Q3 2020 | 2020-09-30 | −65.37% | — |
| Q1 2016 | 2016-03-31 | −577.55% | — |
| Q4 2015 | 2015-12-31 | −215.09% | — |
Biolargo return on equity trends
Over the last five fiscal years, Biolargo's return on equity increased from −1,137.83% to −235.62%, a change of +902.21 percentage points. The latest reported quarter, Q1 2026, shows −116.85%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biolargo source filings ↗